Podcast

Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020

A podcast featuring an interview with Prof. Kausik Ray centered around the latest inclisiran data presented at ESC Congress 2020.

This episode of the Practical Cardiology Podcast features an interview with Prof. Kausik Ray, Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Disease Prevention and the Deputy Director of the Imperial Clinical Trial Unit at the Imperial College London. The subject of the current interview is the latest data from the ORION program examining inclisiran presented at the European Society of Cardiology (ESC) Congress 2020.

Currently under review for the treatment of primary hyperlipidemia by both the European Medicines Association and the US Food and Drug Administration, the first-in-class investigational treatment for hyperlipidemia has the potential to drastically improve disease management for a number of patients.

During the conversation, Ray offers perspective and insights into a pair of analyses presented at the conference and also explains why he thinks physicians should be comfortable prescribing inclisiran to patients, once approved, based on clinical trial data associated with the agent.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.